epTools vs CardioGenetics

Trusted for over 15 years by heart rhythm professionals worldwide, epTools is a collection of useful tools for the evaluation of heart rhythm disorders. It is available on iPhone and iPad devices. Resources include algorithms used to localize arrhythmia substrates and reference guides to assist in the identification and, management of cardiac rhythm disorders and tools to calculate commonly used measurements and risk scores. Peer-reviewed algorithms are implemented by tools via an intuitive user interface. References are provided. Tools guide the user or AI through a series of questions to arrive at an answer while providing a graphical visualization of their progress and result of their analysis. Use of the save path to image feature allows users to save an image of the current decision path when using many of the decision analysis tools included. These images, which appear in the photo album, may be useful to communicate findings with colleagues. Included tools: Preexcitation variant localization: Arruda, Milstein, Taguchi , D'Avila, Li, Pambrun, Baek and Crinion and O'Leary et al. Atrial tachycardias: Ellenbogen and Kistler et al (localization ) De Ponti et al tool (calculates the appropriate mapping window for isthmus identification) Miyazaki et al (localizes macro reentrant ATs based on pacing responses) Ischemic ventricular tachycardia localization: Miller, Segal and Andreu et al) Idiopathic ventricular tachycardia and premature ventricular contraction: Ito, Park and Enriquez et al (localization) ABC-VT Risk Score Differentiation of left vs right ventricular outflow tract sites: QRS-RVA Interval V₂S/V₃R Index TZ Index V₂ Transition ratio R/S-wave Amplitude, R-Wave Duration, R-wave amplitude, V₂QRSI40 and RV₁-₃ indices. Differentiate endocardial from epicardial VTs: Maximum deflection index Daniels and Berruezo et al criteria Differentiate SVT from VT: Brugada, Verckei and Moccetti et al Disease Assessment: Consensus criteria for ARVD/C and Short QT Syndrome 5-yr risk of SCD in HCM (O'Mahon et al, and AHA)and LQTS (1-2-3-LQTS-Risk) 5-yr risk of life threatening VTA with LMNA variant Inadequate DFT safety margin (Hsu et al ) LA arrhythmogenic substrate (Kosiuk et al, D'Ambrosio et al) 30-day mortality after PPM and ICD lead extraction (Brunner et al) 1-4 year mortality in 1° prevention ICD placement (Bilchick et al, SHOCKED) Shanghai score (Brugada Syndrome), VT prediction in ARVD/C (Cadrin-Tourigny et al.) Suspicious Index In Lyme Carditis (SILC) PADIT and BLISTER CIED infection risk Misc: Confirm conduction system capture with LBBAP. myPace personalized heart rate calculator A CIED/electrocautery manager is included. Detailed preoperative plans can be created and shared by text or email. Clinical guidelines and consensus statement resource i CHADS₂, CHA₂DS₂VASc and ATRIA stroke risk, HAS-BLED bleeding risk scores, QT correction heart rate (Bazett or Fredericia, Hodges) and left bundle branch block (Bogosian and Yankelson et al)

Every inherited cardiomyopathy evaluation warrants meticulous, accurate, and evidence-based risk stratification. CardioGenetics compiles validated calculators, diagnostic frameworks, and a live clinical trial finder in your pocket. USED AT THE BEDSIDE Whether you are presenting at a multidisciplinary cardiomyopathy board, interpreting a new pathogenic variant, or seeing your first LMNA patient, CardioGenetics gives the same tools with the evidence and models behind every number. ASCVD RISK ALIGNED WITH THE 2026 GUIDELINES Calculate 10-year risk with AHA PREVENT (ages 30–79), compare against the legacy Pooled Cohort Equations, integrate coronary artery calcium via the MESA score, and interpret Lipoprotein(a) with a built-in risk multiplier. Every result maps directly to the 2026 ACC/AHA dyslipidemia guideline statin thresholds, risk-enhancing factors, and CAC decision pathways. GENE-SPECIFIC SUDDEN CARDIAC DEATH RISK Not all cardiomyopathies carry the same arrhythmic risk. CardioGenetics includes dedicated calculators for HCM (ESC 2014 Risk-SCD), ARVC (Cadrin-Tourigny), LMNA (Wahbi, ESC 2023-adapted), PLN p.Arg14del (Verstraelen), DSP (ERADOS, Eur Heart J 2024), FLNC (Gigli, JAMA Cardiol 2025), and PKP2-specific guidance. Each cross-referenced to the latest ESC 2023 and AHA/ACC 2024 guidelines. DIAGNOSTIC FRAMEWORKS AT YOUR FINGERTIPS Confirm diagnoses before you risk-stratify. Built-in criteria include the 2020 Padua Criteria for arrhythmogenic cardiomyopathy, AHA/ACC 2024 and ESC 2023 HCM diagnostic standards, LVNC scoring (Jenni, Petersen, Stöllberger), and DCM phenotyping. FIND THE RIGHT CLINICAL TRIAL Browse actively enrolling studies for Lp(a), HCM, ACM/ARVC, DSP, LMNA, and PLN with interactive U.S. state and European enrollment maps. Every trial includes its NCT identifier and a direct link to ClinicalTrials.gov. DESIGNED FOR WHAT WE ACTUALLY DO IN CLINIC • Search any calculator, diagnosis, or trial from a single search bar • Tap a risk score and see the full mathematical model, original citation, and DOI • View sensitivity analyses and interactive risk curves • Share lay-language summaries during patient-facing discussions • Cross-navigate between diagnostic confirmation and risk stratification in one tap TRUST BUT VERIFY: Every calculator reproduces its published equation with full variable definitions and baseline coefficients. There are no "black boxes" here, no proprietary modifications. Tap any citation to access the original published manuscript. INTENDED USERS: Cardiologists · Electrophysiologists · Genetic Counselors · Cardiology Fellows and Residents · Medical Students · Advanced Practice Providers · Inherited Cardiovascular Disease Teams Developed by Mark E. Pepin, MD, PhD, FESC. All risk models are derived from peer-reviewed literature and their original sources. This app is a clinical decision-support aid for healthcare professionals and does not replace clinical judgment, institutional protocols, or shared decision-making. Not FDA-cleared or CE-marked.